Search research articles
Contact Us
Filters
Showing results (261-270 of 272) with videos related to
Page
of 28
Sort By:
Iscience
|
June 29, 2026
Pan-cancer analysis reveals Rho kinase addiction as a vulnerability of de-differentiated cancer cells
Jaume Barcelo, Yumiko Teigen, Joshua Alexander James Martin, et al.
European Urology
|
April 9, 2026
Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [<sup>177</sup>Lu] Lu-PSMA-617 (ANZUP1901)
Louise Emmett, Nathan Papa, Oliver Sartor, et al.
European Journal of Human Genetics : EJHG
|
January 10, 2019
Genetic architecture of laterality defects revealed by whole exome sequencing
Alexander H Li, Neil A Hanchard, Mahshid Azamian, et al.
Frontiers in Global Women'S Health
|
December 10, 2025
Clinical care processes for early postpartum haemorrhage diagnosis: a nested observational study within the E-MOTIVE trial
Kristie-Marie Mammoliti, Fernando Althabe, Christina Easter, et al.
The Lancet. Global Health
|
October 18, 2025
When are postpartum haemorrhages diagnosed? A nested observational study within the E-MOTIVE cluster-randomised trial
Kristie-Marie Mammoliti, James Martin, Adam Devall, et al.
BJOG : an International Journal of Obstetrics and Gynaecology
|
August 4, 2025
When Is Postpartum Haemorrhage Treatment Initiated? A Nested Observational Study Within the E-MOTIVE Trial
Kristie-Marie Mammoliti, Fernando Althabe, Christina Easter, et al.
Archives of Disease in Childhood
|
August 28, 2023
External validation of a multivariable prediction model for identification of pneumonia and other serious bacterial infections in febrile immunocompromised children
Alexander James Martin, Fabian Johannes Stanislaus van der Velden, Ulrich von Both, et al.
The Lancet. Oncology
|
April 15, 2024
[<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
Louise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
The Lancet. Oncology
|
February 16, 2025
Overall survival and quality of life with [<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial
Louise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
The New England Journal of Medicine
|
May 9, 2023
Randomized Trial of Early Detection and Treatment of Postpartum Hemorrhage
Ioannis Gallos, Adam Devall, James Martin, et al.
Page
of 28
Search research articles
Search
Showing results (261-270 of 272) with videos related to
Sort By:
Page
of 28
Iscience
|
June 29, 2026
Pan-cancer analysis reveals Rho kinase addiction as a vulnerability of de-differentiated cancer cells
Jaume Barcelo, Yumiko Teigen, Joshua Alexander James Martin, et al.
European Urology
|
April 9, 2026
Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [<sup>177</sup>Lu] Lu-PSMA-617 (ANZUP1901)
Louise Emmett, Nathan Papa, Oliver Sartor, et al.
European Journal of Human Genetics : EJHG
|
January 10, 2019
Genetic architecture of laterality defects revealed by whole exome sequencing
Alexander H Li, Neil A Hanchard, Mahshid Azamian, et al.
Frontiers in Global Women'S Health
|
December 10, 2025
Clinical care processes for early postpartum haemorrhage diagnosis: a nested observational study within the E-MOTIVE trial
Kristie-Marie Mammoliti, Fernando Althabe, Christina Easter, et al.
The Lancet. Global Health
|
October 18, 2025
When are postpartum haemorrhages diagnosed? A nested observational study within the E-MOTIVE cluster-randomised trial
Kristie-Marie Mammoliti, James Martin, Adam Devall, et al.
BJOG : an International Journal of Obstetrics and Gynaecology
|
August 4, 2025
When Is Postpartum Haemorrhage Treatment Initiated? A Nested Observational Study Within the E-MOTIVE Trial
Kristie-Marie Mammoliti, Fernando Althabe, Christina Easter, et al.
Archives of Disease in Childhood
|
August 28, 2023
External validation of a multivariable prediction model for identification of pneumonia and other serious bacterial infections in febrile immunocompromised children
Alexander James Martin, Fabian Johannes Stanislaus van der Velden, Ulrich von Both, et al.
The Lancet. Oncology
|
April 15, 2024
[<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
Louise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
The Lancet. Oncology
|
February 16, 2025
Overall survival and quality of life with [<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial
Louise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
The New England Journal of Medicine
|
May 9, 2023
Randomized Trial of Early Detection and Treatment of Postpartum Hemorrhage
Ioannis Gallos, Adam Devall, James Martin, et al.
Page
of 28